Should You Forget ExxonMobil and Buy Cameco Stock Instead?

The article favors Cameco over ExxonMobil, arguing uranium demand may outpace slowly increasing supply as nuclear energy resurges. Exxon shares are up more than 47% year to date as Brent crude stays above $100 per barrel, while Cameco shares are down 11%; Cameco trades at 45 times forward earnings and has roughly 28 million pounds of annual delivery contracts, with uncommitted volume for 2029 and 2030. Bank of America projects spot uranium could reach $130 per pound, up 44%; if prices stay around $100 for two years, Cameco’s average realized price is projected to rise to $80 from $67.79 in Q2.

Analysis

The relative-value case is more compelling than an outright “replace XOM with Cameco” call. XOM’s earnings are unusually exposed to whether the current oil-price premium persists; a de-escalation in Iran or weaker demand could unwind some of that premium quickly, although its integrated business may cushion the downside. CCO offers a different, longer-duration driver: sustained utility contracting and new nuclear demand could support uranium prices, but spot-price forecasts do not translate immediately into realized prices. The key transmission is the price and tenor of new contracts, not the spot quote alone.

The market may be underestimating contracting leverage if utilities are forced to secure future supply, but the article’s upside case is vulnerable to execution and valuation: a high earnings multiple leaves CCO exposed if contracting is delayed, supply responds faster than expected, or expected price gains are already embedded. Competitors such as Kazatomprom and other uranium producers could also bring supply to market, limiting price realization. Conversely, persistent underinvestment and slow project ramp-ups would strengthen the contracting thesis.

Near term (days), oil headlines and positioning can dominate both stocks. Over 1–3 months, watch uranium term-contract pricing, utility procurement, and company production/realized-price updates. Over 6–18 months, supply growth versus reactor demand is the structural test. Verify CCO’s delivery commitments, production outlook, and realized-price sensitivity before sizing. Thesis-breakers: easing geopolitical risk alongside falling oil, CCO failing to secure improved contract terms, or evidence that uranium supply is expanding faster than demand.

Key Decisions for Investors

• Prefer a staged relative-value position—long CCO against a partial XOM underweight—rather than an outright XOM exit. Scale in on CCO weakness, since its valuation makes entry price consequential; keep the position sized for commodity volatility.
• Treat CCO’s uncommitted future volumes as an option on contract repricing, not guaranteed near-term earnings. Upgrade conviction only if disclosed term prices and contract volumes improve; spot uranium strength alone is insufficient confirmation.
• Use XOM as the nearer-term hedge against persistent oil tightness. Reduce the relative-value exposure if Iran-related disruption escalates or Brent strength is accompanied by upward revisions to XOM guidance; reconsider if geopolitical risk recedes and oil prices retreat.
• Before adding to CCO, verify production guidance, delivery coverage, realized-price sensitivity, and utility contracting data. If contract conversion stalls or supply additions accelerate, avoid chasing the uranium narrative; reassess after the next relevant company update.